AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2
Today, AchilleS Vaccines, a biotech company based in Siena (Italy), announced the successful industrial development of a novel monoclonal antibody (mAb) to treat COVID-19. The treatment, patented by Prof Rino Rappuoli’s MAD Lab and developed by AchilleS, could greatly improve access to COVID-19 treatment and has several advantages compared to conventional mAbs: it can be administered intramuscularly, avoiding the risks of hospitalization. Additionally, this mAb is highly potent and the low dosage treatment offers significant health and cost benefits.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005376/en/
The AchilleS antibody project ‘mAbCo19’ will now be further tested in the clinic, possibly leading to an emergency market authorization this summer. AchilleS is developing this new therapeutic in cooperation with Toscana Life Sciences (TLS) and several partners, such as ExcelGene, Menarini Biotech and IBI Lorenzini.
"This event, for a small company like ours, is really something to be proud of." says Riccardo Baccheschi, CEO of AchilleS. “By continuing to play our role as an enthusiastic contributor to this potentially market-shaping compound, we will further support and materially coordinate the TLS-sponsored clinical and regulatory processes, hopefully up to market licensing. We hope to actively contribute to the elimination of this pandemic in Europe and in the world and to the return to a normal life for all of us, our collaborators and our loved ones ".
Rino Rappuoli, Director of MAD Lab TLS and inventor of the mAb said: “We are very happy to see that our monoclonal continues to perform extremely well not only against the wild type virus but also against the emerging variants.”
In June 2020 AchilleS received a substantial investment from the EU Malaria Fund (EUMF) to develop vaccines for malaria, other infectious diseases, as well as for the ‘mAbCo19’ project. The EUMF is a public-private partnership providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally.
“The development of this treatment against COVID-19 is very timely and much needed.” says Holm Keller, Executive Chairman of kENUP Foundation. “It shows that small- and medium-sized companies play an important role in the fight against COVID-19 and Malaria. We are grateful for the important work of AchilleS, TLS and Menarini.”
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CGTN5.3.2021 14:04:14 CET | Press release
CGTN: China Outlines Plan to Address Economic Challenges in Next 5 Years
MA-EVERBRIDGE5.3.2021 13:32:10 CET | Press release
Everbridge Awarded Revolutionary New Public Warning Patent for Technology that Automates the Selection of the Optimal Communications Channels to Reach the Broadest, Hyper-Targeted Populations – as Fast as Possible – During a Crisis
CA-ANDERSEN-GLOBAL5.3.2021 11:12:10 CET | Pressemeddelelse
Andersen Global styrker sin tilstedeværelse med jordansk advokatfirma
INFORMATION-SERVICES5.3.2021 10:02:13 CET | Press release
COVID-19’s Economic Pinch Drives More Nordic Enterprises Toward Business Process Automation for Competitive Edge
MAISON-D’ANGELANN5.3.2021 09:54:13 CET | Press release
International Fashion Designer Anna Chybisova Draws Major Investments Worth $9 Million for her Brand Maison d’Angelann
XLIFE-SCIENCES-AG5.3.2021 08:50:09 CET | Press release
Xlife Sciences AG (XLS): Joint Venture With anfass Life Technologies
MOODY’S-ANALYTICS5.3.2021 08:32:07 CET | Press release
Moody’s Analytics Wins IFRS 9 Solution Provider of the Year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom